CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company"), today announces that the patent covering the use of AZD5904 in male infertility has now been granted in Canada, completing the approval of this patent in all key pharmaceutical target markets.

CDT believes that the extensive geographical coverage of this patent combined with its more recent composition of matter application provides a strong IP position for development of AZD5904 in male infertility as discussions continue regarding potential licensing and strategic partnering opportunities.

Originally licensed from AstraZeneca, AZD5904 benefits from an extensive clinical safety package alongside pre-clinical validation in an area of significant unmet medical need and a continually growing market.